Triple Endocrine Therapy for Metastatic Breast Cancer
Author Information
Author(s): M Bontenbal, JA Foekens, SWJ Lamberts, FH de Jong, W LJ van Putten, HJ Braun, JThM Burghouts, GHM van der Linden, JGM Klijn
Primary Institution: Erasmus University, Rotterdam
Hypothesis
Can a combination of tamoxifen, a somatostatin analogue, and an antiprolactin improve treatment outcomes for post-menopausal women with metastatic breast cancer compared to tamoxifen alone?
Conclusion
The combination therapy showed a higher objective response rate and longer median time to progression compared to tamoxifen alone, suggesting potential benefits of the combined treatment.
Supporting Evidence
- 36% of patients treated with tamoxifen alone had an objective response.
- 55% of patients treated with combination therapy had an objective response.
- Median time to progression was 33 weeks for tamoxifen alone and 84 weeks for combination therapy.
Takeaway
This study tested a new treatment for breast cancer that combines three medicines, and it seemed to work better than just one medicine alone.
Methodology
22 post-menopausal patients were randomized to receive either tamoxifen alone or a combination of tamoxifen, CV 205-502, and octreotide, with follow-up for endocrine and anti-tumour effects.
Potential Biases
Potential bias due to the small number of patients and the exploratory nature of the study.
Limitations
The small sample size limits the ability to draw definitive conclusions.
Participant Demographics
All participants were post-menopausal women with metastatic breast cancer.
Statistical Information
P-Value
p=0.006 for prolactin levels, p=0.02 for insulin levels
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website